

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

BIOGEN INTERNATIONAL GMBH and
BIOGEN MA INC.,

Plaintiff,

v.

AMNEAL PHARMACEUTICALS INC., et
al.,

Defendants.

Civil Action No. 17-823-MN (consolidated)

JOINT TRIAL EXHIBIT LIST

PRESIDING JUDGE						PLAINTIFF'S COUNSEL	COURT REPORTER
Judge Maryellen Noreika						James B. Monroe, Esq.	Dale Hawkins
DATES OF TRIAL						DEFENDANT'S COUNSEL	COURTROOM DEPUTY
December 6, 2019 to December 13, 2019						J.R. McNair, Esq. Todd Werner, Esq. Timothy Peterson, Esq.	Mark Buckson
JTX No.	PTX No.	DTX No.	Date Offered	Marked	Admitted	Description of Exhibits	Witness
	PTX004		12/11/2019	Y	Y	BG00012 Phase IIb MS	Dr. O'Neil
	PTX032		12/9/2019	Y	Y	BG00012 - EOP2 Meeting Minutes	Dr. Dawson
	PTX042		12/11/2019	Y	Y	Email from Anne Saia Re: Reminder - Ad Hoc CTRB Meeting - BG12 MS, Thursday, February 19, 2004	Dr. O'Neil
	PTX046		12/11/2019	Y	Y	Clinical Trial Review Board Meeting Agenda Item Meeting Minutes	Dr. O'Neil
	PTX047		12/12/2019	Y	Y	CDT Meeting Discussion Minutes - December 18th 2003	Dr. Bozic
	PTX055		12/9/2019	Y	Y	A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study - Version 1	Dr. Dawson
	PTX057		12/9/2019	Y	Y	A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study - Version 1	Dr. Dawson
	PTX062		12/12/2019	Y	Y	Tecfidera Press Release	Jarosz
	PTX063		12/12/2019	Y	Y	Article: "The Greatest Thing Since Sliced Bread Has Arrived for MS Patients"	Jarosz

JTX No.	PTX No.	DTX No.	Date Offered	Marked	Admitted	Description of Exhibits	Witness
	PTX064		12/12/2019	Y	Y	Biogen Newspaper Article	Jarosz
	PTX089		12/12/2019	Y	Y	Integrated Product Plan: Intended Usage	Jarosz
	PTX098		12/12/2019	Y	Y	Q3 2018: US MS Neuro Northstar Full Report	Jarsz
	PTX099 A		12/9/2019	Y	Y	Curriculum vitae Katherine T. Dawson	Dr. Dawson
	PTX100		12/9/2019	Y	Y	Declaration of Katherine T. Dawson, M.D.	Dr. Dawson
	PTX102		12/11/2019	Y	Y	Email from Cara Lansden Re: BG-12 MS CDT meeting minutes	Dr. O'Neil
	PTX103		12/9/2019	Y	Y	Minutes from BG-12 MS CDT meeting on 05 July 2006	Dr. Dawson
	PTX110		12/9/2019	Y	Y	BG-12 Program Team Meeting Minutes	Dr. Dawson
	PTX112		12/9/2019	Y	Y	BG-12 Program Team Meeting Minutes	Dr. Dawson
	PTX113		12/9/2019	Y	Y	Email from Gina Smith Re: BG-12 ESTIMATE regarding cost/timeline of 480mg	Dr. Dawson
	PTX114		12/9/2019	Y	Y	BG-12: EOP2 Meeting Discussion "Q&A Approach"	Dr. Dawson
	PTX150		12/11/2019	Y	Y	Email from Gilmore O'Neill Re: BG00012 Slides for Psoriasis	Dr. O'Neil
	PTX161		12/11/2019	Y	Y	Email from Cara Lansden Re: Resourcing for BG-12 Contingencies	Dr. O'Neil
	PTX162		12/9/2019	Y	Y	Minutes from BG-12 MS CDT Meeting on June 14 2006	Dr. Dawson
	PTX167		12/11/2019	Y	Y	Email from Gilmore O'Neill Re: BG00012	Dr. O'Neil
	PTX174		12/11/2019	Y	Y	Document entitled "Highlights of Prescribing Information"	Dr. Wynn
	PTX176		12/11/2019	Y	Y	Document entitled, "Highlights of Prescribing Information for DMF Delayed-Release Capsules for Oral Use"	Dr. Wynn
	PTX177		12/11/2019	Y	Y	Document entitled, "Highlights of Prescribing Information for DMF Delayed-Release Capsules for Oral Use"	Dr. Wynn
	PTX178		12/11/2019	Y	Y	Document entitled, "Highlights of Prescribing Information for DMF Delayed-Release Capsules for Oral Use"	Dr. Wynn
	PTX182		12/11/2019	Y	Y	Highlights for Prescribing Information (Tecfidera)	Dr. Wynn
	PTX183		12/11/2019	Y	Y	Highlights of Prescribing Information Re Dimethyl Fumarate Delayed-Release Capsules (revised 3/2017)	Dr. Wynn
	PTX184		12/11/2019	Y	Y	Highlights of Prescribing Information Re Dimethyl Fumarate Delayed-Release Capsules (revised 7/2017)	Dr. Wynn
	PTX190		12/11/2019	Y	Y	Highlights of Prescribing Information Dimethyl Fumarate Delayed-Release Capsules	Dr. Wynn

JTX No.	PTX No.	DTX No.	Date Offered	Marked	Admitted	Description of Exhibits	Witness
	PTX206		12/11/2019	Y	Y	Document entitled "Highlights of Prescribing Information"	Dr. Wynn
	PTX207		12/11/2019	Y	Y	Document entitled "Highlights of Prescribing Information"	Dr. Wynn
	PTX211		12/12/2019	Y	Y	Complaint, Pharmathen S.A. vs. Lachman Consultant Services, Inc.	Jarosz
	PTX213		12/9/2019	Y	Y	Dr. Lindsey's Multiple Sclerosis Website	Dr. Lindsey
	PTX214		12/9/2019	Y	Y	Dr. Lindsey's Multiple Sclerosis Website, ECTRIMS Sept. 2009	Dr. Lindsey
	PTX215		12/9/2019	Y	Y	Dr. Lindsey's Multiple Sclerosis Website, ECTRIMS Sept. 2011	Dr. Lindsey
	PTX216		12/9/2019	Y	Y	Dr. Lindsey's Multiple Sclerosis Website, AAN April 2012	Dr. Lindsey
	PTX379		12/9/2019	Y	Y	Opposition against European patent EP 2 801 355 by Biogen MA Inc., at D4, filed Feb. 19, 2016	Dr. Dawson
	PTX384		12/11/2019	Y	Y	BiogenF10010560 – BiogenF10010568	Dr. O'Neil
	PTX386		12/11/2019	Y	Y	BiogenF10113121 – BiogenF10113121	Dr. O'Neil
	PTX391		12/11/2019	Y	Y	BiogenF10153077 – BiogenF10153079	Dr. O'Neil
	PTX392		12/11/2019	Y	Y	BiogenF10153084 – BiogenF10153086	Dr. O'Neil
	PTX403		12/11/2019	Y	Y	Exhibit 2125 in IPR2018-01403, Duddy, M. Getting to Grips 2011, Newcastle upon Tyne, UK, November 2011	Dr. Duddy
	PTX417		12/11/2019	Y	Y	U.S. Patent Application No. 13/372,426, October 12, 2012 Final Office Action	Dr. Wynn
	PTX418		12/11/2019	Y	Y	U.S. Patent Application No. 13/372,426, December 12, 2012 Reply to Final Office Action	Dr. Wynn
	PTX419		12/11/2019	Y	Y	U.S. Patent Application No. 13/372,426, December 26, 2012 Notice of Allowance	Dr. Wynn
	PTX429		12/11/2019	Y	Y	MS Decisions aid, Multiple Sclerosis (MS) Trust, https://www.mstrust.org.uk/about-ms/ms-treatments/ms-decisions-aid	Dr. Duddy
	PTX457		12/12/2019	Y	Y	https://www.tecfidera.com/en_us/home/about/benefits.html	Jarosz
	PTX459		12/12/2019	Y	Y	https://www.tecfidera.com/en_us/home/getting-started/managing-side-effects.html	Jarosz
	PTX460		12/12/2019	Y	Y	https://www.tecfiderahcp.com/en_us/home/getting-started/starting-tecfidera.html	Jarosz
	PTX461		12/12/2019	Y	Y	https://www.tecfiderahcp.com/en_us/home/tolerability-and-safety/safety.html	Jarosz
	PTX494		12/12/2019	Y	Y	Biogen Inc. Form 10-K for the fiscal year ended December 31, 2018 ("Biogen 2018 10-K")	Jarosz

JTX No.	PTX No.	DTX No.	Date Offered	Marked	Admitted	Description of Exhibits	Witness
	PTX518		12/12/2019	Y	Y	Grabowski, H., G. Long, R. Mortimer, and A. Boyo, "Updated Trends in US Brand-Name and Generic Drug Competition," Journal of Medical Economics Vol. 19, No. 9 (2016): 836-844	Jarosz
	PTX547		12/12/2019	Y	Y	https://search.proquest.com/docview/15354119907accountid=41158	Jarosz
	PTX651		12/12/2019	Y	Y	IPR2015-01993 Ex. 2068	Jarosz
	PTX677		12/11/2019	Y	Y	Email "C1900 ENS abstracts" January 31, 2006	Dr. O'Neil
	PTX732		12/12/2019	Y	Y	Tabs 1-24 to The Jarosz Expert Report	Jarosz
	PTX743		12/9/2019	Y	Y	Biogen Interference Exhibit 2132; meeting minutes from July 14, 2006	Dr. Dawson
	PTX748		12/9/2019	Y	Y	Biogen Interference Exhibit 2130; BG-12 Phase 3 Data DEFINE First Look (slides)	Dr. Dawson
	PTX749		12/9/2019	Y	Y	Biogen Interference Exhibit 2376; FDA Statistical Review of Phase III studies	Dr. Dawson
		DTX001	12/6/2019	Y	Y	U.S. Patent No. 8,399,514	Dr. Yong
		DTX002	12/6/2019	Y	Y	U.S. Provisional Application No. 60/888,921	Dr. Yong
		DTX003	12/6/2019	Y	Y	International Patent Publication No. WO 2008/097596 (International Application No. PCT/US2008/001602)	Dr. Yong
		DTX004	12/9/2019	Y	Y	U.S. Application No. 12/526,296 - Preliminary Amendment Under 37 C.F.R. § 1.115	Dr. Lukashey
		DTX012	12/9/2019	Y	Y	Prosecution History of U.S. Patent No. 8,399,514	Dr. Stobbe
		DTX017	12/11/2019	Y	Y	U.S. Patent Application No. 13/372,426 - Declaration of Richard A. Rudick, M.D. Under 37 C.F.R. § 1.132	Dr. Duddy
		DTX024	12/11/2019	Y	Y	Email to Rebecca Conaghan etc. from Gilmore N. Oneill re BG00012	Dr. O'Neil
		DTX034	12/9/2019	Y	Y	Program/Clinical Development Team Minutes	Lansden
		DTX037	12/9/2019	Y	Y	Email chain re: Gilmore O'Neill's performance in 2004	Lansden
		DTX038	12/9/2019	Y	Y	Email chain re: Commercial strategy question	Lansden
		DTX039	12/9/2019	Y	Y	Email chain re: BG-12 MS CRB Draft	Lansden
		DTX047	12/12/2019	Y	Y	Email re: BG-12 MS CDT meeting minutes (Interference No. 106,023 - Biogen Exhibit 2316)	Dr. Bozic
		DTX063	12/9/2019	Y	Y	Email re: BG12 MS EOP2 meeting package Review Notice - COMMENTS DUE ON JULY 7	Dr. Dawson
		DTX071	12/9/2019	Y	Y	BG-12 Program Team Meeting Minutes	Dr. Lindsey

JTX No.	PTX No.	DTX No.	Date Offered	Marked	Admitted	Description of Exhibits	Witness
		DTX080	12/9/2019	Y	Y	Letter to Carol Holquist (FDA) from Nadine D. Cohen at Regulatory Affairs re: BG00012 (dimethyl fumarate): Multiple Sclerosis -- IND 73,061 Correspondence re: REQUEST FOR PROPRIETARY NAME REVIEW: Primary Name: SYNAPLINTM (dimethyl fumarate) Alternate Name: SANCTELfNTM (dimethyl fumarate)	Dr. Lindsey
		DTX094	12/12/2019	Y	Y	Email re: BG'12 phase 2	Dr. Bozic
		DTX099	12/11/2019	Y	Y	Email Chain re: BG12 in MS Phase IIb	Dr. O'Neil
		DTX100	12/12/2019	Y	Y	Email Chain re: CTRB (ad hoc) Meeting Minutes for BG 12 MS - February 19, 2004	Dr. Bozic
		DTX101	12/9/2019	Y	Y	Email chain: Draft commercial slides for BG-12 MC Meeting	Sibbold
		DTX102	12/9/2019	Y	Y	Email chain re: 73061 with attachment: BG00012 End-Of-Phase 2 Meeting Information Package Submitted on July 28, 2006	Dr. Lindsey
		DTX166	12/9/2019	Y	Y	U.S. Patent Application 2014/0163100 A1	Dr. Dawson
		DTX167	12/9/2019	Y	Y	LinkedIn Profile of Matvey Lukashev	Dr. Lukashey
		DTX168	12/9/2019	Y	Y	BG-12 Program Team Meeting Minutes	Dr. Lukashey
		DTX175	12/9/2019	Y	Y	Supplemental Amendment and Reply Under 37 C.F.R. § 1.111	Dr. Lukashey
		DTX182	12/9/2019	Y	Y	U.S. Patent No. 7,619,001	Dr. Stobbe
		DTX247	12/11/2019	Y	Y	O'Neill, G.M. Powerpoint: BG00012 in RRMS: Update From Phase 2 Study, National Faculty Meeting, Bonita Springs Jan. 27-29, 2006	Dr. O'Neil
		DTX296	12/9/2019	Y	Y	Email re: BG-12CTRB Prep Doc	Sibbold
		DTX297	12/9/2019	Y	Y	Email chain re: a few notes / requests...	Sibbold
		DTX302	12/9/2019	Y	Y	Email chain re: DISSCUSSION / Bid Dosing in BG12 MS	Sibbold
		DTX303	12/9/2019	Y	Y	Powerpoint: BG-12 MS Go/No Go Discussion	Sibbold
		DTX319	12/9/2019	Y	Y	Press Release, "Phase II Study Of Oral Compound BG-12 Meets Primary Endpoint In Multiple Sclerosis," BOWIRE2k (2006) (Mylan IPR - Exhibit 1005)	Dr. Stobbe
		DTX320	12/9/2019	Y	Y	Biogen Idec, Efficacy [sic] and Safety of BG00012 in MS: Double-Blind, Placebo- Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis, ClinicalTrials.gov, https://clinicaltrials.gov/archive/NC/T0016870/1/2005_09_14 (last updated on Sept. 14, 2005) ("Clinical Trial NCT00168701")	Dr. Stobbe

JTX No.	PTX No.	DTX No.	Date Offered	Marked	Admitted	Description of Exhibits	Witness
		DTX321	12/9/2019	Y	Y	Prosecution History of U.S. Patent No. 7,320,999 (U.S. Application No. 10/197,077)	Dr. Stobbe
		DTX322	12/11/2019	Y	Y	Fumaderm Label - Summary of Product Characteristics Fumaderm Initial	Dr. Duddy
		DTX323	12/9/2019	Y	Y	ICH Harmonised Tripartite Guideline Dose-Response Information to Support Drug Registration E4	Dr. Stobbe
		DTX324	12/9/2019	Y	Y	PCT International Application WO 2006/037342 A2 (Nilsson)	Dr. Lindsey
		DTX325	12/9/2019	Y	Y	PCT International Application WO 2007/042034 A1 (Nilsson)	Dr. Stobbe
		DTX327	12/9/2019	Y	Y	Kappos, et al., Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: Results of a phase 2 study (Abstract O108), J. Neurology, 253(Suppl. 2):II/27 (2006) (Mylan IPR - Exhibit 1007)	Dr. Stobbe
		DTX328	12/9/2019	Y	Y	Kappos, et al., "A Randomised, Placebo-Controlled Phase 2 Trial Of A Novel Oral Fumarate, BG00012, In Patients With Relapsing-Remitting Multiple Sclerosis," (2016) PTAB Declaration of Gilmore O'Neill (Mylan IPR - Exhibit 1034)	D. Stobbe
		DTX329	12/9/2019	Y	Y	Kappos et al., Poster "Efficacy of a Noval Oral Single Agent Fumarate, BG00012, In Patients with Relapsing-Remitting Multiple Sclerosis: Results of a Phase II Study" (2006)	Dr. Stobbe
		DTX332	12/9/2019	Y	Y	Nieboer et al., "Fumaric Acid Therapy in Psoriasis: A Double-Blind Comparison Between Fumaric Acid Compound Therapy and Monotherapy with Dimethylfumaric Acid Ester," Dermatologica 181:33-37 (1990)	Dr. Stobbe
		DTX334	12/9/2019	Y	Y	Richter et al., "The Impact of Reducing Dose Frequency on Health Outcomes" Clinical Therapeutics, Vol. 25, No. 8:2307-35 (2003)	Dr. Stobbe
		DTX338	12/9/2019	Y	Y	U.S. Patent Application Publication Pub. No.: US 2003/0018072 A1 (Joshi)	Dr. Stobbe
		DTX339	12/9/2019	Y	Y	U.S. Patent Application Publication Pub No.: US 2009/0304790 A1 (Nilsson)	Dr. Stobbe
		DTX340	12/9/2019	Y	Y	U.S. Patent No. US 6,509,376 B1 (Joshi)	Dr. Stobbe
		DTX341	12/9/2019	Y	Y	U.S. Patent No. 7,320,999 B2 (Joshi)	Dr. Stobbe
		DTX345	12/9/2019	Y	Y-Objection OR	PTAB Final Written Decision 35 U.S.C. 318(a) and 37 C.F.R. 42.73 (Coalition IPR -Paper 63)	Dr. Stobbe

JTX No.	PTX No.	DTX No.	Date Offered	Marked	Admitted	Description of Exhibits	Witness
		DTX346	12/9/2019	Y	Y- Objection OR	PTAB Decision Institution of Inter Partes Review 35 U.S.C. 314 (Mylan IPR - Paper 12)	Dr. Stobbe
		DTX367	12/12/2019	Y	Y	Biogen Idec to Acquire Fumapharm AG; Consolidates Ownership of Oral Compound BG-12 Being Studied for Multiple Sclerosis - BIOWIRE2K	Hofmann
		DTX369	12/12/2019	Y	Y	Form 10-K, Biogen Idec Inc.	Hofmann
		DTX377	12/9/2019	Y	Y	Brief of Appellee Biogen MA Inc. (Appeal No. 2017-2109, Fed. Cir.)	Dr. Lindsey
		DTX406	12/9/2019	Y	Y	Biogen Idec Announces Positive Top-Line Results from the First Phase 3 Trial Investigating Oral BG-12 In Multiple Sclerosis	Dr. Lindsey
		DTX441	12/9/2019	Y	Y	Press Release, "Oral Compound BG-12 Achieves Primary Endpoint In Phase II Study Of Relapsing-Remitting Multiple Sclerosis; Treatment With BG-12 Led To Statistically Significant Reductions In MRI Measures," BIOWIRE2K (2006)	Dr. Stobbe
		DTX446	12/9/2019	Y	Y	Fox, et al., "Placebo-Controlled Phase 3 Study Of Oral BG-12 Or Glatiramer In Multiple Sclerosis," New Engl J. Med. 367:1087-97 (2012)	Dr. Stobbe
		DTX447	12/9/2019	Y	Y	Gold et al., "Placebo-Controlled Phase 3 Study of Oral BG-12 For Relapsing Multiple Sclerosis," N Engl J Med 367:1098-107 (2012)	Dr. Stobbe
		DTX451	12/11/2019	Y	Y	Kappos, et al., "Efficacy And Safety Of Oral Fumarate In Patients With Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIB Study," Lancet 1463-72 (2008)	Dr. O'Neil
		DTX457	12/9/2019	Y	Y	Prosecution History of U.S. Patent Application No. 12/526,296 - Amendment To Specification.	Dr. Lindsey
		DTX463	12/9/2019	Y	Y	FDA correspondence re. EOP2 meeting w. Meeting Minutes	Dr. Lindsey
		DTX464	12/9/2019	Y	Y	Curriculum Vitae of Gary H. Stobbe, M.D.	Dr. Stobbe
		DTX465	12/12/2019	Y	Y	Curriculum Vitae of Ivan Hofmann	Hofmann
		DTX466	12/9/2019	Y	Y	Curriculum Vitae of Dr. John W. Lindsey, M.D.	Dr. Lindsey
		DTX467	12/6/2019	Y	Y	Curriculum Vitae of Dr. V. Wee Yong, Ph.D.	Dr. Yong
		DTX471a	12/11/2019	Y	Y	CV of Dr. Wynn	Dr. Wynn
		DTX478	12/12/2019	Y	Y	Curriculum Vitae of John C. Jarosz	Jarosz
		DTX483	12/12/2019	Y	Y	Tecfidera - Orange Book Approved Deug Products website - Patent and Exclusivity	Hofmann
		DTX492a	12/11/2019	Y	Y	CV of Dr. Duddy	Dr. Duddy

JTX No.	PTX No.	DTX No.	Date Offered	Marked	Admitted	Description of Exhibits	Witness
		DTX495	12/11/2019	Y	Y	Emerging therapies in multiple sclerosis (Martin Duddy) Presentation (Mylan IPR - Biogen Ex. 2124)	Dr. Duddy
		X	12/6/2019			Expert testimony of Dr. Wee Yong	
		X	12/9/2019			Expert testimony of Dr. John Lindsey	
		X	12/9/2019			Video deposition of Dr. Matvey Lukashev	
		X	12/9/2019			Expert testimony of Dr. Gary Stobbe	
		X	12/9/2019			Video deposition of William Sibbold	
		X	12/9/2019			Video deposition of Cara Lansden	
	X		12/9/2019			Witness testimony of Dr. Katherine Dawson	
	X		12/11/2019			Expert testimony of Dr. Martin Duddy	
	X		12/11/2019			Witness testimony of Dr. Gilmore O'Neil	
	X		12/11/2019			Expert testimony of Dr. Daniel Wynn	
	X		12/12/2019			Expert testimony of John Jarosz	
		X	12/12/2019			Expert testimony of Ivan Hofmann	
		X	12/12/2019			Video deposition of Dr. Carmen Bozic	